Trial Profile
Effects of rosiglitazone and sulphonylureas on ischaemic burden, blood pressure and novel risk markers inclusive of vascular function in patients with chronic stable angina and type 2 diabetes mellitus: a randomised, double-blinded study
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 18 Jul 2023
Price :
$35
*
At a glance
- Drugs Rosiglitazone (Primary) ; Gliclazide
- Indications Angina pectoris; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 05 Nov 2005 New trial record.